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Abstract
Background: Subcutaneous terbutaline (SQ terbutaline) infusion by pump is used in pregnant women as a prolonged
(beyond 48–72 h) maintenance tocolytic following acute treatment of preterm contractions. The effectiveness and safety of
this maintenance tocolysis have not been clearly established. We aimed to systematically evaluate the effectiveness and
safety of subcutaneous (SQ) terbutaline infusion by pump for maintenance tocolysis.
Methodology/Principal Findings: MEDLINE, EMBASE, CINAHL, the Cochrane Library, the Centre for Reviews and
Dissemination databases, post-marketing surveillance data and grey literature were searched up to April 2011 for relevant
experimental and observational studies. Two randomized trials, one nonrandomized trial, and 11 observational studies
met inclusion criteria. Non-comparative studies were considered only for pump-related harms. We excluded case-reports
but sought FDA summaries of post-marketing surveillance data. Non-English records without an English abstract were
excluded. Evidence of low strength from observational studies with risk of bias favored SQ terbutaline pump for the
outcomes of delivery at ,32 and ,37 weeks, mean days of pregnancy prolongation, and neonatal death. Observational
studies of medium to high risk of bias also demonstrated benefit for other surrogate outcomes, such as birthweight and
neonatal intensive care unit (NICU) admission. Several cases of maternal deaths and maternal cardiovascular events have
been reported in patients receiving terbutaline tocolysis.
Conclusions/Significance: Although evidence suggests that pump therapy may be beneficial as maintenance tocolysis, our
confidence in its validity and reproducibility is low, suggesting that its use should be limited to the research setting.
Concerns regarding safety of therapy persist.
Citation: Gaudet LM, Singh K, Weeks L, Skidmore B, Tsertsvadze A, et al. (2012) Effectiveness of Terbutaline Pump for the Prevention of Preterm Birth. A
Systematic Review and Meta-Analysis. PLoS ONE 7(2): e31679. doi:10.1371/journal.pone.0031679
Editor: Zulfiqar A. Bhutta, Aga Khan University, Pakistan
Received September 22, 2011; Accepted January 16, 2012; Published February 21, 2012
Copyright:  2012 Gaudet et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was funded under Contract No. HHSA-290-2007-10059-I-EPC3 from the Agency for Healthcare Research and Quality, U.S. Department of
Health and Human Services. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the
Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. The funders had no role in study design, data collectiona n d
analysis, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: moansari@ohri.ca
Introduction
Preterm birth is defined as delivery before the completion of the
37th week of gestation and affects 13 percent (542 893 births in
2006) of live births in the United States (http://www.cdc.gov/
nchs/fastats/birthwt.htm) [1]. Approximately 40 percent of
preterm births occur after the spontaneous onset of preterm labor
[2]. Long-term neonatal sequelae of prematurity such as bron-
chopulmonary dysplasia, grade III/IV intraventricular hemor-
rhage and retinopathy of prematurity determine the overall quality
of life for the child and the family.
Terbutaline sulfate has been used off-label in selected patients as
a maintenance therapy to inhibit uterine contractions for extended
periods of time following primary tocolysis with first-line agents.
Terbutaline, a b-sympathomimetic drug, acts to relax smooth
muscle in the bronchial tree, blood vessels and myometrium [3].
Maternal side effects are common, and can include serious adverse
reactions such as pulmonary edema, myocardial ischemia, cardiac
arrhythmias, hypotension, and metabolic alterations [3]. Despite
previous reviews which questioned the effectiveness and safety of
subcutaneous terbutaline infusion, the use of such therapy is not
uncommon in the United States [3,4]. The exact frequency of use
of subcutaneous terbutaline infusion for the prevention of preterm
birth is not known.
This review, commissioned by the Agency for Healthcare
Research and Quality through its established stakeholder topic
nomination process, aims to systematically review and meta-
analyze the evidence examining the efficacy, effectiveness, and
harms of SQ terbutaline pump for preventing preterm labor,
compared with placebo, conservative treatment, or any other
active intervention. We investigated the clinical effectiveness and
harms of pump therapy by systematically retrieving, appraising
and synthesizing evidence on neonatal health outcomes and
outcomes of maternal and neonatal harm. Surrogate outcomes,
such as birthweight and prolongation of pregnancy were also
examined. The potential confounding effects of maternal activity
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the incidence of pump-related outcomes. Particularly in light of a
recent ‘‘black box’’ warning issued by the FDA, this review
provides a contemporary and definitive summary of the available
literature on the benefits and harms of terbutaline maintenance
tocolysis.
Methods
We followed a pre-specified and peer-reviewed study protocol
(Information S1). The full evidence report (Information S2),
including search strategies and a detailed list of a priori outcomes,
risk of bias assessment and detailed evidence tables are available at
www.effectivehealthcare.ahrq.gov/reports/final.cfm.
Ethics
Ethics approval was not required for this review, as there is no
potential for individual patient identification.
Searching
We searched Ovid MEDLINEH In-Process & Other Non-
Indexed Citations and Ovid MEDLINEH (1950 to April 1 2011);
OVID EMBASE (1980 to April 1 2011); CINAHL via
EBSCOhost (1985 to December 7, 2009), the Cochrane Library
via the Wiley interface (April 1, 2011) (including CENTRAL,
Cochrane Database of Systematic Reviews, DARE, HTA, and
NHS EED), and the Centre for Reviews and Dissemination (CRD)
databases (January 2, 2010). We hand-searched the bibliographies
and text of review articles, letters to editors, and commentaries and
the reference lists of included studies for additional references. We
also reviewed grey literature sources and information received
from pharmaceutical companies. Finally, we reviewed the FDA
summary of post-marketing data to assess risk of maternal harm.
Selection
Two reviewers screened abstracts and full-text reports with
conflicts resolved by consensus or third party adjudication. Studies
were included if they met the following criteria: evaluated
pregnant women between 24–36 weeks gestation having had
acute preterm labor arrested with primary tocolytic therapy;
included at least one group that was administered SQ terbutaline
pump; and assessed one of the specified outcomes (primary
neonatal outcomes, surrogate outcomes, maternal harms, neonatal
harms, pump-related outcomes and long-term childhood out-
comes).
Validity Assessment
For each study outcome, we assessed confounding and risk of
selection, performance, detection and attrition bias. Selected items
from the McMaster Quality Assessment Scale of Harms (http://
hiru.mcmaster.ca/epc/mcharm.pdf) were also included. The
overall risk of bias ratings were designated as high, medium, or
low. Outcomes were rated as high risk of bias if there was a major
flaw in the study. Separately, we evaluated the potential for
financial conflict of interest.
Following published guidance for the Effective Health Care
Program two reviewers graded the strength of evidence for
incidence of delivery at various gestational ages, mean prolonga-
tion of pregnancy, bronchopulmonary dysplasia, significant
intraventricular hemorrhage (grade III/IV), neonatal death, death
within initial hospitalization, and maternal withdrawal due to
adverse effects [5]. The guidance stipulates that the strength of
evidence be rated as insufficient, low, moderate or high to reflect
our confidence on the validity and reproducibility of evidence
synthesis. According to the guidance, evidence was to be
considered insufficient (i.e. inability to conclude) when there were
no studies, studies showing opposite direction of effect, or when
confidence intervals were wide enough to incorporate the
possibilities of benefit, no difference or harms. Also, the strength
of evidence based on observational studies conventionally starts off
with a grade of low which is upgraded only when there is
demonstration of a dose-response relationship, large effect size, or
an effect despite confounding towards null. Generalisability or
applicability of evidence was also rated as per previous guidance
[6].
Data Abstraction
One reviewer extracted data into a standardized electronic form
and assessed study risk of bias and applicability. Extraction items
included general study characteristics (e.g. year of publication,
study design), population characteristics (e.g. inclusion/exclusion
criteria, age, race, level of activity), intervention characteristics
(e.g. dose, duration, details about comparators, level of care), and
outcomes with their estimates. A second reviewer verified
outcomes data and study risk of bias assessments. Ratings for
level of care, level of activity, and assessments of applicability were
verified by a clinical expert.
Study Characteristics
Aside from case reports, all types of study designs were
considered because evidence from experimental studies is often
limited for reviews of comparative effectiveness [7–9]. Non-
comparative studies (i.e. case series) were assessed only for pump-
related harms, such as incidence of pump failure, missed doses, or
overdose and maternal harms. Non-English language records
without an English abstract were excluded. We also excluded case
reports, but in a post hoc decision sought FDA summaries of post-
marketing data highlighting serious harms.
Pump efficacy was examined for pre-specified subpopulations of
women but harms were investigated across subgroups. The
subgroups included women delivering extremely preterm
(,28+0 weeks), very preterm (28+0t o3 1 +6 weeks), preterm
(32+0t o3 3 +6 weeks), and later preterm (34+0 and 36+6 weeks);
with multiple gestation; of different racial subgroups; with previous
preterm birth; with history of preeclampsia and; with and without
recurrent preterm labor.
Quantitative Data Synthesis
We performed a meta-analysis of the RCTs with a random
effects model when they were clinically and methodologically
similar [10]. To assess statistical heterogeneity and its magnitude,
we used Cochran’s Q (a=0.10) and the I
2 statistic respectively.
Odds ratios (ORs) were calculated for dichotomous outcomes and
mean differences for continuous outcomes. Analyses were
performed using Comprehensive Meta Analysis version 2.2.046
or version 2.2.055 (NJ, USA). We did not perform meta-analysis of
the observational studies because of potential differences in
confounders, nor did we combine studies of singleton and multiple
pregnancies. Small number of included studies precluded meta-
regression and exploration of heterogeneity in effect estimates.
Results
Flow of Included Studies
The flow of retrieved records through the phases of literature
screening is detailed in Figure 1. Fourteen independent studies and
1 companion article were included in the review [11,12].
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Table 1 presents general summary characteristics of the
included studies. Most studies were observational, and included
cohorts and case series. Two studies were RCTs and one was a
nonrandomized trial. Sample sizes ranged from 9 to 1 366, but
over 70 percent of studies included at least 200 subjects (average
2916395). Despite meta-analysis, evidence from the two small
RCTs remained underpowered for differences in the outcomes of
benefit and harms (total N=94).
All studies were from the United States and patients were
recruited either from single center study sites or from a national
proprietary database run by Matria Healthcare. This database
provides an outpatient perinatal program consisting of 24-hour
nursing and pharmacy support, home uterine activity monitoring,
individualized education, and provision of tocolytic therapy to
women with preterm labor. Because five studies originated in the
Matria database, and not all reported geographic region and/or
years over which participants were recruited, the question of
overlap in patients across these studies was an important concern.
Comparator groups included placebo, no treatment, oral terbu-
taline, oral nifedipine, and mixed oral tocolytics.
The definition of labor was unclear in 36 percent of the included
studies. The remaining studies included women with persistent
contractions and cervical change. Parenteral magnesium sulfate
was often the primary tocolytic to arrest acute preterm labor. In
several studies, only women with two or more episodes of preterm
labor (i.e. recurrent preterm labor) were eligible for inclusion
[11,13–20]. Some studies were conducted exclusively in women
with singleton gestation [13,15,17,18,21,22], while a few studies
evaluated women with twins only [16,19]. Some studies may have
included women less than 24 weeks gestational age, but data for
such participants could not be separated [11,15–19,21,23].
Figure 1. Flow of retrieved records through screening and inclusion.
doi:10.1371/journal.pone.0031679.g001
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are summarized in Table 2. No studies presented data on
concomitant medications, body mass index (BMI), history of
preeclampsia, cervical position, cervical consistency, cervical
station, Bishop’s Score, or fetal fibronectin.
Risk of Bias Assessment
Studies with important group imbalances in baseline charac-
teristics or prognostic factors were rated as high risk of bias
(Table 1). Those with no identifiable flaws but with incomplete
reporting of information for risk assessment were judged to be of
medium risk of bias. Although the randomization procedures in
the two RCTs were appropriate, we rated one RCT as high risk of
bias because more than 90 percent of eligible participants declined
to participate, the study was underpowered, and blinding was
ineffective. The two case series were judged to be of medium risk
of bias because neither study provided clear definitions for the
pump-related harm outcomes and several criteria such as
compliance, adequacy of sample size, and selective outcome
reporting, were unclear.
Quantitative Data Synthesis
Neonatal Health Outcomes. One retrospective cohort with
medium risk of bias, presented evidence of low strength suggesting
SQ terbutaline pump may decrease the risk of neonatal death
compared with oral tocolytics in women with recurrent preterm
labor and twin gestation (OR=0.09, 95 percent CI: 0.01, 0.70)
(Table 3) [19].
Three retrospective cohort studies reported non-significant
differences in rate of stillbirth in women with recurrent preterm
labor and single or twin gestation [17–19]. However, these studies
were likely underpowered, given the small number of events
(,1%). Sparse evidence from underpowered studies addressed
clinically important neonatal outcomes including necrotizing
Table 1. Summary characteristics of the included studies.
CHARACTERISTIC NUMBER OF STUDIES REFERENCES
Study Design RCT 2 [21,24]
Nonrandomized trial 1 [22]
Prospective Cohort 2 [13,14]
Retrospective Cohort 7 [11,15–19,25]
Case Series 2 [20,23]
Participant Recruitment Single Center Sites 9 [11,13,14,20–25]
Matria Database 5 [15–19]
Funding Industry 2 [21,23]
NonIndustry 3 [11,14,25]
Not Reported 9 [13,15–20,22,24]
Comparator
* Oral Nifedipine 3 [15–17]
Oral Terbutaline 4 [11,22,24,25]
Oral Tocolytics 3 [14,18,19]
Placebo (saline pump) 2 [21,24]
No treatment 1 [13]
No comparison group 2 [20,23]
Primary Tocolytic Treatment IV Magnesium Sulfate only 1 [20]
IV Magnesium Sulfate and/or other agents 5 [13,21–24]
Not Reported 8 [11,14–19,25]
Gestation Singletons only 6 [13,15,17,18,21,22]
Twins only 2 [16,19]
Singletons and Twins 2 [23,24]
Not Reported 4 [11,14,20,25]
Definition of Labor Not reported 5 [15,17–19,25]
Risk of Bias
* Low 1 [21]
Medium 7 [11,16,17,19,20,22,23]
High 7 [13–15,18,22,24,25]
Outcomes Improvement of Neonatal Outcomes 6 [13,17–19,21,24]
Improvement of Surrogate Outcomes 12 [11,13–19,21,22,24,25]
Maternal Harm Outcomes 6 [13,18,19,21,22,25]
Neonatal Harm Outcomes 1 [24]
Outcomes of pump failure 3 [20,23,24]
Abbreviations: RCT=randomized controlled trial; IV=intravenous.
*One study contained two comparison groups [24]. Risk of bias of one study differed by outcome [22].
doi:10.1371/journal.pone.0031679.t001
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Characteristic Number of Studies that Reported Characteristic Value
Mean maternal age 12 [11,13–16,18,19,21–25] 21.6–32.4 years
Mean GA at preterm labor 6 [13,15–19] 29.5–31.6 weeks
Mean GA at start of therapy 6 [11,20–24] 29.1–32.2 weeks
Race 5 [11,13,19,21,25]* European(white); Hispanic; African; Asian; Other (‘‘nonwhite’’)
Comorbidities 2 [13,23] bacterial vaginosis; asthma; urinary tract infection; fibroids; chronic
hypertension/pregnancy induced hypertension; HELLP syndrome
History of preterm birth 7 [13,16–19,21,23] 10.8–75%
Cerclage 6 [15–19,23] 2.8–13.1%
Gravidity 2 [18,24] 2.6 (mean) [18]; 2.25, 2.5, 2.6 (medians) [24]
Parity 3 [11,14,24] 1.2 (mean) [11], 1.4 (mean) [14]; 0.5, 0.5, 0.7 (medians) [24]
Membrane status 8 [11,13–16,20,21,23] Intact
Mean cervical length 1 [20] 0.2 cm
Mean cervical dilation 5 [11,13,20,21,24] 1.7–2.9 cm
Cervical effacement 1 [21] 50% (median)
Abbreviations: GA=gestational age; HELLP syndrome=hemolysis, elevated liver function values, low platelet count.
*None of these studies reported separate effect estimates for different races.
doi:10.1371/journal.pone.0031679.t002
Table 3. Strength of evidence for the outcomes of interest.
Outcome Population; Comparator NStudies NSubjects NEvents Effect Estimate SoE Domains
* SoE
Neonatal death
{ Twins+RPTL; Oral tocolytics 1 [19] 706 12 OR=0.09 (0.01, 0.70) Medium; N/A; Direct; Precise Low
Singleton+RPTL; Oral nifedipine 1 [17] 284 0 OR=1.00 (0.02, 50.75) Medium; N/A; Direct; Imprecise Insufficient
Significant IVH
(Grade III/IV)
{
Singleton+RPTL; No treatment 1 [13] 60 4 OR=0.30 (0.02, 5.85) High; N/A; Direct; Imprecise Insufficient
Incidence of delivery
,32 weeks
Twins+RPTL; Oral nifedipine 1 [16] 656 192 OR=0.47 (0.33, 0.68) Medium; N/A; Indirect; Precise Low
Twins+RPTL; Oral tocolytics 1 [19] 706 124 OR=0.52 (0.35, 0.76) Medium; N/A; Indirect; Precise Low
Singleton + RPTL; Oral nifedipine 2 [15,17] 1650 106 OR=0.20–0.29 (0.07–
0.16, 0.52–0.61)
{
High/Medium; Consistent;
Indirect; Precise
Low
Singleton+RPTL; Oral tocolytics 1 [18] 558 37 OR=0.21 (0.09, 0.50) High; N/A; Indirect; Precise Low
Singleton+RPTL; No treatment 1 [13] 60 21 OR=0.04 (0.00, 0.65) High; N/A; Indirect; Precise Low
Incidence of delivery
,37 weeks
{
Singleton+RPTL; Oral nifedipine 2 [15,17] 1650 925 OR=0.72–0.75 (0.47–
0.58, 0.90–1.20)
{
High/Medium; Consistent;
Indirect; Imprecise
Insufficient
Singleton+RPTL; Oral tocolytics 1 [18] 558 318 OR=0.70 (0.50, 0.98) High; N/A; Indirect; Precise Low
Singleton+RPTL; No treatment 1 [13] 60 50 OR=0.04 (0.01, 0.23) High; N/A; Indirect; Precise Low
Singleton/Multiple+RPTL; Oral
terbutaline
1 [11] 64 38 OR=0.10 (0.03, 0.32) Medium; N/A; Indirect; Precise Low
Pregnancy
prolongation (days)
{
Twins+RPTL; Oral nifedipine 1 [16] 656 N/A MD=7.20 (4.10, 10.30) Medium; N/A; Indirect; Precise Low
Singleton+RPTL; Oral nifedipine 2 [15,17] 1650 N/A MD=6.20–7.50 (0.79–
4.94, 10.06–11.61)
{
High/Medium; Consistent;
Indirect; Imprecise
Insufficient
Singleton+RPTL; Oral tocolytics 1 [18] 558 N/A MD=5.50 (2.28, 8.72) High; N/A; Indirect; Precise Low
Singleton+RPTL; No treatment 1 [13] 60 N/A MD=25.30 (16.77, 33.83) High; N/A; Indirect; Precise Low
Abbreviations: IVH=intraventricular hemorrhage; MD=mean difference; N=number; N/A=not applicable; OR=odds ratio; RPTL=recurrent preterm labor;
SoE=strength of evidence.
*SoE domains are presented in the following order: Risk of Bias; Consistency; Directness; Precision.
{RCT evidence was available for neonatal death [24], significant IVH [21], delivery ,37 weeks [21], and pregnancy prolongation [21,24]. There were no events of
neonatal death or significant IVH. Nonsignificant differences were reported for incidence of delivery ,37 weeks and pregnancy prolongation. The RCT evidence was
not graded because it did not apply to any of the subgroups of interest.
{These studies were not pooled. There was risk of double counting of participants across these studies.
doi:10.1371/journal.pone.0031679.t003
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therefore, inconclusive [13,24]. No data were available for
bronchopulmonary dysplasia, death within initial hospitalization,
periventricular leukomalacia, and seizures.
Mean Gestational Age at Delivery. Larger cohort studies in
women with recurrent preterm labor and single or twin gestation
demonstrated consistent benefit of SQ terbutaline pump
compared with oral tocolytics or no treatment (although there is
a high risk of bias in the available data) (Figure 2). For women with
recurrent preterm labor and singleton pregnancies, the difference
in gestational age ranged from 0.70 to 3.40 weeks (95% CI, lower
bound range 0.28 to 1.80; upper bound range 0.98 to 5.00)
favoring SQ terbutaline pump. In pregnancies complicated by
recurrent preterm labor in twins, the difference in gestational age
from two cohorts was 0.70 weeks (95 percent CI, lower bound
range 0.43 to 0.48; upper bound range 0.92 to 0.97) (Table 4)
[13,15–19].
Incidence of Delivery at Various Gestational Ages. As
with other outcomes, the strength of evidence surrounding
gestational age at delivery was low. The SQ terbutaline pump
consistently appeared to reduce the odds of delivering ,32 weeks
in women with recurrent preterm labor with twin pregnancies in
the six Matria-based cohort studies (Table 3). The odds ratios
ranged from 0.04 to 0.52 (95% CI, lower bound range 0.00 to
0.35; upper bound range 0.50 to 0.76) [13,15–19].
The risk of any preterm delivery (,37 weeks) was also assessed.
Low strength of evidence favored SQ terbutaline pump compared
with oral tocolytics or no treatment in women with recurrent
preterm labor (Table 3). Four of five cohort studies with important
risk of bias reported statistically significant reduction in the odds
of delivery ,37 weeks (OR 0.04 to 0.75; 95 percent CI, lower
bound range 0.01 to 0.58; upper bound range 0.23 to 1.20)
[11,13,15,17,18].
Prolongation of Pregnancy. As with other outcomes, the
strength of evidence for prolongation of pregnancy was insufficient
or low (Table 3). Evidence favored SQ terbutaline pump in
women with recurrent preterm labor or twin gestation in cohort
studies. The range for mean number of days of pregnancy
prolongation was 5.50 to 25.30 (95 percent CI, lower bound range
0.79 to 16.77; upper bound range 8.72 to 33.83) (Table 3) [13,15–
18]. This evidence came from five cohort studies of medium to
high risk of bias. In one Matria-based cohort study, more women
in the SQ terbutaline pump group had pregnancy prolonged .7
days compared with women who received oral nifedipine
(OR=7.84, 95 percent CI, 3.59, 17.12) [15]. Other Matria-
based studies reported statistically significant benefits in favor of
the pump compared with oral tocolytics for prolongation .14
days (OR range=1.93 to 3.47, 95 percent CI, lower bound range
0.87 to 2.34; upper bound range 2.65 to 5.15) [15–19].
Birthweight. Cohort studies of women with recurrent pre-
term labor and single or twin gestation demonstrated statistically
significant differences in mean birthweight in favor of SQ
terbutaline pump compared with oral tocolytics or no treatment
(range of mean difference in grams=136 to 721, 95 percent CI,
lower bound range 83 to 355; upper bound range 189 to 1087)
(Figure 3 and Table 5) [13,16–19].
Studies reporting the incidence of low birthweight (,2500 g)
found statistically significant differences in favor of SQ terbutaline
pump compared with no treatment or oral tocolytics (OR
range=0.24 to 0.64, 95 percent CI, lower bound range 0.06 to
0.51; upper bound range 0.62 to 0.96) [13,15–19]. Most of the
studies reporting the incidence of very low birthweight (,1500 g)
also found statistically significant differences in favor of the pump
(OR range=0.22 to 0.46, 95 percent CI, lower bound range 0.07
to 0.29; upper bound range 0.60 to 1.06) [16–19]. The studies that
reported birthweight were mostly of medium or high risk of bias.
NICU Admission. For incidence of NICU admission,
statistically significant differences favoring SQ terbutaline pump
were reported in studies of medium or high risk of bias (OR range
0.28 to 0.72, 95 percent CI, lower bound range 0.08 to 0.58; upper
Figure 2. Mean gestational age at delivery (weeks). Statistical heterogeneity for the RCT pooled estimate: I
2=0.0 percent, p-value.0.05.
* There were discrepancies in the information presented in the text and table of this paper [22]. Mean gestational age at delivery for SQ terbutaline
pump was reported as 36.6 weeks in table (as reported above) and 37.2 weeks in text. The value 36.6 weeks was used to calculate difference in
means. SQ=subcutaneous.
doi:10.1371/journal.pone.0031679.g002
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differences in favor of SQ terbutaline pump were also reported for
NICU length of stay in these cohort studies (range of mean
difference in days: 23.50 to 217.90, 95 percent CI, lower bound
range 25.26 to 232.88; upper bound range 21.74 to 23.54)
[13,15,18,19].
Other Surrogate Outcomes. One cohort study reported a
non-significant difference between SQ terbutaline pump and oral
tocolytics in requirement for ventilation among infants with NICU
admission [18]. Pregnancy prolongation index was reported in two
cohorts studies of medium and high risk of bias [11,13]. Both
found statistically significant differences in favor of SQ terbutaline
pump compared with either no treatment or oral terbutaline
(mean difference range=0.14 to 0.41, 95 percent CI, lower bound
range 0.26 to 0.56; upper bound range 0.02 to 0.26).
Maternal Harms. There were no reports of maternal death
in the included studies. Underpowered studies demonstrated
indeterminate results for pulmonary edema, therapy discon-
tinuation and maternal hyperglycemia (i.e., type II error cannot
be excluded) [13,18,19,21,22,25]. One prospective cohort of
Table 4. Summary table for mean gestational age at delivery.
Study Design
(number of studies) Population Comparator(s) Risk of Bias
RCT (2) Women with singleton gestation from Birmingham Hospital (n=52) [21] Placebo Low
Women with singleton or twin gestation from the University of Iowa Hospital
(n=42) [24]
Placebo and oral
terbutaline
High
Nonrandomized Trial (1) Women with singleton gestation from the Hospital of the University of
Pennsylvania (n=91) [22]
Oral terbutaline High
Prospective Cohort (2) Women with singleton gestation and RPTL (n=60) [13] No treatment High
Likely included a mixture of women with single and multiple gestation (n=69) [14] Oral tocolytics High
Retrospective Cohort (6) Women with singleton gestation and RPTL from the Matria database (n=1366) [15] Oral nifedipine High
Women with singleton gestation and RPTL from the Matria database (n=284) [17] Oral nifedipine Medium
Women with singleton gestation and RPTL from the Matria database (n=558) [18] Oral tocolytics (95.3%
received oral terbutaline)
High
Women with twin gestation and RPTL from the Matria database (n=656) [16] Oral nifedipine Medium
Women with twin gestation and RPTL from the Matria database (n=706) [19] Oral tocolytics (92.3%
received oral terbutaline)
Medium
Likely included a mixture of women with single and multiple gestation (n=69) [25] Oral terbutaline High
Abbreviations: RCT=randomized controlled trial; RPTL=recurrent preterm labor.
doi:10.1371/journal.pone.0031679.t004
Figure 3. Mean birthweight (grams). Statistical heterogeneity for the RCT pooled estimate: I
2=0.0 percent, p-value.0.05. * There were
discrepancies in the information presented in the text and table of this paper [22]. The numbers reported in the table were used to calculate the
difference in means. However, the text reported group data with numbers switched for the groups (i.e. SQ terbutaline pump: 32296584 and oral
terbutaline: 30176303). SQ=subcutaneous.
doi:10.1371/journal.pone.0031679.g003
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labor suggested that pump use was associated with increased
tachycardia/nervousness (OR=25.48, 95 percent CI:1.23, 526.6)
[13]. No data within the study settings were identified for
withdrawal due to adverse events, heart failure, hypokalemia,
myocardial infarction and refractory hypotension.
By 2009, 16 maternal deaths and 12 cases of maternal
cardiovascular events (hypertension, myocardial infarction, tachy-
cardia, arrhythmias and pulmonary edema) in patients receiving
terbutaline tocolysis had been reported to the FDA. Three of the
maternal deaths and three cardiovascular adverse events were
reported in patients receiving SQ terbutaline pump therapy
(http://www.fda.gov/Drugs/DrugSafety/ucm243539.htm).
Neonatal Harms. Data for neonatal harms were very sparse.
Only one small RCTcomparingSQterbutalinepump withplacebo
and oral terbutaline demonstrated non-significant differences for
neonatal hypoglycemia.
Incidence of Pump Failure. Two case series and one RCT
reported outcomes related to the pump device [20,23,24]. In a
case series of 51 women, one subject had dislodgment of catheter
(2 percent, exact central CI: 0.5 percent, 10 percent) and there was
one pump malfunction (2 percent, exact central CI: 0.5 percent,
10 percent) [23]. No infusion site infections or mechanical failures
were observed in a case series of 9 women [20]. An underpowered
RCT demonstrated indeterminate results for the outcomes of local
pain and local skin irritation [24]. No data were available for
missed doses or overdoses.
Assessment of Confounding by Level of Activity and Level
of Care. Only a small number of studies could be rated for level
of activity and level of care, precluding an exploration of the effect
of these variables on maternal and neonatal outcomes. Qualitative
assessments did not yield any further insights.
Applicability. Table 6 summarizes the applicability of the
body of evidence. The majority of evidence pertained to women
with recurrent preterm labor and singleton gestation. Very little is
known about the study population’s demographic and clinical
characteristics, placing significant restrictions on the generalisability
of results. Furthermore, the possibility that subjects represented a
selective group of participants remains a concern.
Discussion
Across several outcomes, the evidence favors subcutaneous
terbutaline pump as maintenance tocolytic therapy for women
with arrested preterm labor. However, our confidence in the
validity and reproducibility of this evidence is low. Most of the
evidence came from biased observational studies that reported
surrogate outcomes only. Furthermore, the safety of the pump
therapy remains unclear, largely because studies lacked power to
detect differences in outcomes of harm.
A total of 14 unique studies comprised the body of evidence
investigating efficacy and harms of SQ terbutaline pump therapy
as maintenance tocolysis in women with arrested preterm labor.
Evidence from the only two included RCTs was underpowered to
detect differences in outcomes of efficacy and harms. Most data
came from observational studies, several of which recruited
subjects from a single Matria database. These studies were at
significant risk of bias and exhibited considerable clinical and
methodological diversity.
While a single study demonstrated improvement in neonatal
death in women with recurrent preterm labor and twin gestation
receiving SQ terbutaline maintenance tocolysis, several studies
presented evidence favoring the pump therapy on surrogate
outcomes of preterm birth. However, the evidence for important
neonatal health outcomes, neonatal harms, and maternal harms
was inconclusive because the studies lacked power to detect
differences in clinical events. Furthermore, there was no data on
the long-term effects of terbutaline infusion on offspring. Although
many decisions regarding SQ terbutaline pump are currently
made on the assumption that short-term outcomes will correlate
well with improved long-term outcomes, rigorous scientific
evaluation is needed to confirm whether such factors lead to
better outcomes in this population.
These findings are consistent with those of two existing reviews
of SQ terbutaline pump [3,4]. As reported by Nanda et al., we
found that the available RCT evidence demonstrated non-
significant differences between the pump and placebo or oral
terbutaline [3]. In agreement with another review, we found that
the RCT and observational evidence is conflicting [4]. We noted
Table 5. Summary table for mean birthweight.
Study Design
(number of studies) Population Comparator(s) Risk of Bias
RCT (2) Women with singleton gestation from Birmingham Hospital (n=52) [21] Placebo Low
Women with singleton or twin gestation from the University of Iowa Hospital
(n=42) [24]
Placebo and oral terbutaline High
Nonrandomized Trial (1) Women with singleton gestation from the Hospital of the University of
Pennsylvania (n=91) [22]
Oral terbutaline High
Prospective Cohort (1) Women with singleton gestation and RPTL (n=60) [13] No treatment High
Retrospective Cohort (6) Women with singleton gestation and RPTL from the Matria database (n=284) [17] Oral nifedipine Medium
Women with singleton gestation and RPTL from the Matria database
(n=558) [18]
Oral tocolytics (95.3%
received oral terbutaline)
High
Women with twin gestation and RPTL from the Matria database (n=656) [16] Oral nifedipine Medium
Women with twin gestation and RPTL from the Matria database (n=706) [19] Oral tocolytics (92.3%
received oral terbutaline)
Medium
Women with RPTL and likely included a mixture of women with single and
multiple gestation (n=64) [11]
Oral terbutaline Medium
Women with single or multiple gestation (n=69) [25] Oral terbutaline High
Abbreviations: RCT=randomized controlled trial; RPTL=recurrent preterm labor.
doi:10.1371/journal.pone.0031679.t005
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pump while cohort studies of limited methodological validity
demonstrated statistically significant effects in favor of the pump
for several outcomes.
Based on post-marketing surveillance data, the FDA has issued a
new warning against the use of terbutaline in general, and
particularly as an injection, as maintenance tocolysis (i.e. beyond
48–72 hours) in pregnant women. The warning is a response to
several cases of poor maternal outcomes in pregnancies treated with
subcutaneous terbutaline. These cases raised concern regarding a
potential causative relationship. It is important to consider that the
outcomesinquestionoccurinfrequentlyinthepregnantpopulation,
even in the absence of terbutaline use. Assessment of the magnitude
of the association between terbutaline use and harm continues to be
challenging, given the rarity of events and the lack of good quality,
well powered studies. Until this relationship is further delineated,
use of terbutaline for the prevention of preterm birth should be
limited to carefully-controlled study settings.
Limitations
The evidence base for this review contained several limitations.
Most of the evidence originated from observational study designs
with significant risk of bias. Important prognostic factors such as
race, socioeconomic status, and fetal fibronectin level were not
reported and co-interventions, such as administration of cortico-
steroids, were rarely described. Moreover, it is uncertain how free
the available evidence is from confounding imposed by restriction
of maternal activity and level of care. While our review of the
literature was comprehensive in capturing comparative evidence
estimating the magnitude of benefits and harms of pump therapy,
one potential and practical limitation was restriction to evidence
reported in the English language.
There are several factors of applicability that should be
considered by maternity care providers and policymakers when
translating the evidence from this review. The majority of
available evidence included women with recurrent preterm labor
(i.e. those with arrested preterm labor following first-line tocolytic
therapy for 48 hours and then presenting with a second episode)
and singleton gestation, with some evidence including women with
twin gestation and recurrent preterm labor. Several studies
included patients from a national proprietary database run by
Matria Healthcare, which provides an outpatient perinatal
program consisting of 24-hour nursing and pharmacy support,
home uterine activity monitoring, individualized education, and
provision of tocolytic therapy to women with preterm labor. These
women received a high standard of care.
It is notoriously difficult to conduct trials to assess the efficacy of
tocolytics. Studies regarding tocolytics have been plagued by the
elusive diagnosis of preterm labor as up to 40 percent of women
diagnosed with preterm labor may not actually be in labor [26]. As
such, a significant proportion of women enrolled in clinical trials of
tocolytic efficacy may not be destined to deliver preterm. A
definitive trial in this domain must include a focus on accurate
diagnosis of preterm labor, perhaps, combining stringent clinical
criteria with factors such as positive fetal fibronectin and shortened
trans-vaginal cervical length. Outcomes to be investigated should
go beyond those of prolongation of pregnancy and birthweight to
hard clinical endpoints of neonatal morbidity. Furthermore, the
trial should include long-term follow-up to assess subsequent
childhood outcomes. It is evidence of improvements in clinical
effectiveness outcomes that can impact clinical decision making,
societal healthcare costs and guideline recommendations.
In conclusion, our systematic review calls into question the
evidence base supporting the current practice of using terbutaline
pump as a maintenance tocolytic agent. We feel strongly that use
of terbutaline infusion for maintenance tocolysis should be
restricted to well-designed, carefully-controlled study settings until
there is clear evidence supporting its use. Further, decision and
policy makers should take into consideration the limitations of the
available data, both in terms of benefit and harm, when
formulating recommendations.
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Table 6. Applicability of the body of evidence.
Population The majority of evidence pertained to women with recurrent preterm labor and singleton gestation in the
United States. Very little information was reported about the study populations’ demographic and clinical
characteristics. Nine of 14 studies (64 percent) included women judged to be in labor on account of persistent
contractions and cervical change. The definition of labor was unclear in other studies. Among the studies that
suggested that the pump was efficacious, 50 percent reported cervical change and contractions as part of the
definition of labor while 50 percent did not report how labor was defined.
Intervention Although there were gaps in reporting, the intervention generally did not pose any serious limitations to
applicability. Very few details were reported on cointerventions that could modify the effectiveness of therapy,
such as administration of corticosteroids. In several studies, participants received specialized outpatient services
from Matria Healthcare.
Comparison Comparators included oral tocolytics, no treatment, and placebo.
Outcomes Surrogate outcomes were the most commonly reported. Data on clinical outcomes, neonatal/maternal harms,
and pump-related outcomes were sparse. Long-term outcomes have not been reported at all.
Timing of Outcomes Measurement The absence of follow-up beyond delivery is a major limitation because important long-term outcomes have not
been evaluated.
Setting All studies were from the United States and participant data were acquired from a national database (Matria) or
from single center sites. Women from the Matria database generally received a high level of care from an
outpatient perinatal program. However, the distribution of regions from which patient data were included into
the national database is unknown and information about the standards followed by the individual practice sites
that provided obstetrical care was not reported. Similarly, for those studies that took place at single center sites,
the standards of care followed at these sites are unclear.
doi:10.1371/journal.pone.0031679.t006
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